Search our Database of Scientific Publications and Authors

I’m looking for a
    Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma.
    Invest Radiol 2016 Feb;51(2):121-6
    From the *Diagnostic and Interventional Radiology, Department of Radiology, Eberhard-Karls University; and †Division of Translational Gastrointestinal Oncology, Department of Internal Medicine I, University of Tübingen, Tübingen, Germany.
    Objectives: The aim of this study was to assess clinical utility of the quantitative perfusion parameter called parenchymal blood volume (PBV), as derived from C-arm-based computed tomography (CT), for immediate posttreatment assessment of drug-eluting bead (DEB) transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC).

    Materials And Methods: Twenty-four patients with early- or intermediate-stage HCC received DEB-TACE. A total of 52 HCC lesions were treated and assessed by C-arm CT before and after intervention. C-arm CT consisted of nonenhanced and contrast-enhanced acquisitions; from these, PBV maps were reconstructed. Lesion diameter, maximum PBV, and unenhanced parenchyma density were assessed before and after treatment. Diameter of visible contrast media deposits as well as residual vascularization was assessed after delivery of DEB. All patients underwent follow-up using cross-sectional imaging. All assessed lesions were evaluated concerning modified Response Evaluation Criteria in Solid Tumors for HCC.

    Results: All treated lesions showed significant decrease in PBV after DEB-TACE (mean difference, -15.61 mL/100 mL, P < 0.0001). Eleven lesions showed residual tumoral perfusion in PBV maps associated with an unfavorable outcome compared with completely treated lesions in terms of a lower tumor shrinkage over time (-0.02 ± 0.49 vs -0.76 ± 0.38; P < 0.0001). A contrast media deposit was seen in 78% of treated HCC lesions with a tendency toward better visibility in encapsulated lesions. Nonenhanced parenchyma density was significantly higher in all treated segments (149.69 ± 58.6 vs 68.42 ± 18.04, P < 0.0001).

    Conclusions: Parenchymal blood volume values as derived from C-arm CT acquisitions in combination with nonenhanced and contrast-enhanced C-arm CT images are useful in posttreatment assessment of DEB-TACE in HCC. Residual tumor perfusion in PBV maps have predictive potential for mid-term tumor response in HCC and could allow a more individualized treatment schedule for DEB-TACE in HCC patients.

    Similar Publications

    C-arm computed tomography parenchymal blood volume measurement in evaluation of hepatocellular carcinoma before transarterial chemoembolization with drug eluting beads.
    Cancer Imaging 2015 Dec 29;15:22. Epub 2015 Dec 29.
    Department of Radiology, Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
    Background: C-arm computed tomography (CT) guided intervention is an increasingly applied technique in transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). The aim of this study was to analyse the value of parenchymal blood volume (PBV) maps acquired during C-arm CT acquisition, for pre-treatment evaluation and planning of TACE in HCC patients.

    Methods: A total of 64 HCC lesions in 29 patients (median age, 73 years, range, 62-77 years) were included in this retrospective study. Read More
    Intraprocedural blood volume measurement using C-arm CT as a predictor for treatment response of malignant liver tumours undergoing repetitive transarterial chemoembolization (TACE).
    Eur Radiol 2016 Mar 27;26(3):755-63. Epub 2015 Jun 27.
    Institute for Diagnostic and Interventional Radiology, Johann Wolfgang Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
    Purpose: To evaluate feasibility of measuring parenchymal blood volume (PBV) of malignant hepatic tumours using C-arm CT, test the changes in PBV following repeated transarterial chemoembolization (TACE) and correlate these changes with the change in tumour size in MRI.

    Methods: 111 patients with liver malignancy were included. Patients underwent MRI and TACE in a 4- to 6-week interval. Read More
    C-arm computed tomography and volume perfusion computed tomography (VPCT)-based assessment of blood volume changes in hepatocellular carcinoma in prediction of midterm tumor response to transarterial chemoembolization: a single center retrospective trial.
    Cancer Imaging 2016 Sep 21;16(1):30. Epub 2016 Sep 21.
    Department of Radiology, Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
    Background: This study aims to evaluate immediate changes in perfusion parameters in hepatocellular carcinoma (HCC) to transarterial chemoembolization (TACE) in C-arm computed tomography (CT) and volume perfusion CT (VPCT) and prediction of midterm tumor response.

    Methods: Twenty-five patients (median age 66, range 61 to 75 years) with 62 HCC lesions undergoing TACE received immediate pre- and post-interventional assessment by C-arm CT and VPCT. Cross-sectional imaging was analyzed at baseline and approximately 12 weeks after TACE according to modified RECIST criteria. Read More
    Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation.
    Eur J Radiol 2015 Dec 11;84(12):2548-54. Epub 2015 Sep 11.
    University of Tübingen, Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str.3, 72076 Tübingen, Germany. Electronic address:
    Objective: Response monitoring of transarterial chemoembolization (TACE) with the help of volume perfusion computed tomography (VPCT) at day one post-TACE and analysis of TACE-impact on tumor and uninvolved liver parenchymal perfusion by using different particles sizes and epirubicin dose.

    Materials And Methods: Institutional review board approved this prospective study. VPCT was performed in the baseline, post-interventional (FU1; 24 h post-TACE) and at follow-up (FU2; median, 81 days) in 45 consecutive patients. Read More